目的 探讨肾炎康复片联合甘精胰岛素注射液治疗糖尿病肾病的临床疗效。方法 选取2015年3月—2016年9月宜昌市第二人民医院收治的糖尿病肾病患者74例作为研究对象，按照随机数字表法分为对照组和治疗组，每组各37例。对照组每晚睡前皮下注射甘精胰岛素注射液，初始剂量8 IU，每3天调整1次，每次调整范围在2～4 IU。治疗组在对照组基础上口服肾炎康复片，5片/次，3次/d。两组患者均连续治疗12周。观察两组的临床疗效，比较两组的血糖、肾功能、炎症反应因子水平的变化。结果 治疗后，对照组、治疗组的总有效率分别为64.86%、89.19%，两组患者临床总有效率比较差异具有统计学意义（P< 0.05）。治疗后，两组患者肌酐（Scr）、24 h尿蛋白定量（Upro）、空腹血糖（FBG）、餐后2 h血糖（2 h PG）均显著降低，同组治疗前后比较差异具有统计学意义（P< 0.05）；且治疗组Scr、Upro显著低于对照组，两组比较差异具有统计学意义（P< 0.05）。治疗后，两组肿瘤坏死因子α（TNF-α）、C反应蛋白（CRP）、转化生长因子（TGF-β1）均显著降低，同组治疗前后比较差异具有统计学意义（P< 0.05）；且治疗组各指标明显低于对照组，两组比较差异具有统计学意义（P< 0.05）。结论 肾炎康复片联合甘精胰岛素注射液治疗糖尿病肾病具有较好的临床疗效，能够改善肾功能，减轻炎症反应，具有一定的临床推广应用价值。

Objective To study the clinical effect of Shenyan Kangfu Tablets combined with Insulin Glargine Injection in treatment of diabetic nephropathy. Methods Patients (74 cases) with diabetic nephropathy in Yichang Second People's Hospital from March 2015 to September 2016 were randomly divided into control and treatment groups according to random number table method, and each group had 37 cases. Patients in the control group were sc administered with Insulin Glargine Injection before bedtime, with an initial dose of 8 IU, adjusted once every 3 d, with a range of 2-4 IU each time. Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and blood glucose, renal function, and inflammatory response factor level in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 64.86% and 89.19%, respectively, and there was difference between two groups (P < 0.05). After treatment, Scr, Upro, FBG, and 2 h PG in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And Scr and Upro in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, TNF-α, CRP, TGF-β1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Insulin Glargine Injection has clinical curative effect in treatment of diabetic nephropathy, can significantly improve renal function, and reduce inflammation response, which has a certain clinical application value.